Alzheimer's Disease Calcium Homeostasis and Channel Modulator Companies

Alzheimer's Disease Calcium Homeostasis and Channel Modulator Companies

Overview

Alzheimer's Disease Calcium Homeostasis and Channel Modulator Companies

Overview

This category covers companies developing next-generation calcium homeostasis modulators for Alzheimer's disease beyond conventional L-type, T-type, and N-type calcium channel blockers. The calcium hypothesis of AD, first proposed by Khachaturian in 1989[@khachaturian1989], posits that dysregulated intracellular calcium signaling is a central driver of neurodegeneration. While traditional calcium channel modulators target surface membrane channels, this field focuses on:

• Calcium-sensing receptor (CaSR) agonists and positive allosteric modulators
• Store-Operated Calcium Entry (SOCE) inhibitors targeting STIM1/ORAI1 axis
• Mitochondrial calcium uniporter (MCU) modulators
• Calmodulin inhibitors and modulators
• Calbindin/parvalbumin pathway enhancers

Scientific Rationale

Calcium-Sensing Receptor (CaSR)

The CaSR is a G protein-coupled receptor (GPCR) that monitors extracellular calcium levels and regulates cellular calcium homeostasis. In the brain, CaSR is expressed in neurons and glia, playing roles in:

• Synaptic plasticity: CaSR activation modulates NMDA receptor function and long-term potentiation
• Neuroprotection: CaSR agonists can reduce excitotoxicity and amyloid-beta toxicity
• Neuroinflammation: CaSR modulates microglial activation states[@calcium_sensing_neuro]

Store-Operated Calcium Entry (SOCE)

SOCE is the major pathway for calcium influx in non-excitable cells and operates in neurons through the STIM1 (stromal interaction molecule 1) and ORAI1 (orai calcium release-activated calcium modulator 1) proteins. Key features:

• ER calcium depletion triggers STIM1 oligomerization and ORAI1 activation
• Excessive SOCE is implicated in amyloid-beta-induced neuronal death
• STIM1/ORAI1 axis is upregulated in AD brains, contributing to calcium overload[@soc_brain_path]

Mitochondrial Calcium Uniporter (MCU)

The MCU complex is the primary pathway for mitochondrial calcium uptake. In AD:

• Calcium overload in mitochondria triggers permeability transition and cell death
• MCU dysfunction contributes to bioenergetic failure in neurons
• Selectivity is critical — global calcium blockade is toxic, but mitochondrial-specific targeting preserves normal neuronal function[@soc_mcdonnell2024]

Calmodulin

Calmodulin is a calcium-binding messenger that transduces calcium signals into cellular responses. In AD:

• Calmodulin-dependent kinases phosphorylate tau at AD-relevant sites
• Calmodulin-regulated phosphodiesterases modulate cAMP signaling
• Calmodulin inhibitors may reduce tau pathology and improve synaptic function[@calmodulin_ad]

Parvalbumin and Calbindin

These calcium-buffering proteins regulate intracellular calcium dynamics. Loss of parvalbumin-positive interneurons is observed in AD, contributing to network hyperexcitability.

Key Companies and Programs

Calcium-Sensing Receptor (CaSR) Modulators

CalciMedica

• Headquarters: La Jolla, California, USA
• Founded: 2007
• Focus: CaSR antagonists for critical care and inflammatory diseases, with emerging CNS applications
• Technology: Novel CaSR modulators targeting allosteric sites
• Relevance: CaSR antagonism may reduce calcium dysregulation in AD neurons by modulating calcium set-point
• See: [CalciMedica](/companies/calcimedica)

NodThera

• Headquarters: Cambridge, Massachusetts, USA / London, UK
• Founded: 2017
• Focus: NLRP3 inflammasome inhibitors; CaSR modulators for neuroinflammation
• Technology: CaSR is upstream of NLRP3 activation — modulating CaSR may reduce neuroinflammatory calcium signals
• Relevance: Addresses calcium dysregulation and neuroinflammation as interconnected AD pathways
• See: [NodThera](/companies/nodthera)

Kal Pharmaceuticals

• Headquarters: Seoul, South Korea
• Focus: CaSR-targeted therapeutics for neurodegeneration
• Lead Programs: KP-001, KP-002 — CaSR modulators in preclinical development for AD
• Technology: Allosteric CaSR modulators optimized for brain penetration
• Relevance: Addresses both neuronal calcium dysregulation and microglial activation

Store-Operated Calcium Entry (SOCE) Inhibitors

CalciMedica

• Program: CM-02 series — SOCE inhibitors targeting STIM1/ORAI1 interaction
• Indication: ALS, Alzheimer's disease
• Stage: Preclinical
• Mechanism: Small molecule inhibitors of STIM1 oligomerization, blocking pathological SOCE without affecting basal calcium signaling
• Preclinical Data: CM-02 reduces amyloid-beta-induced calcium influx in primary neurons, with improved survival vs. vehicle
• See: [CalciMedica](/companies/calcimedica)

Calportrix (Academic Spinout)

• Origin: University of Cambridge spinout
• Focus: ORAI1 channel inhibitors for neurodegeneration
• Technology: Structure-based design of selective ORAI1 blockers vs. ORAI2/ORAI3
• Stage: Discovery
• Relevance: ORAI1 inhibition reduces calcium overload while sparing essential calcium-dependent processes

Kypha

• Headquarters: Rennes, France
• Focus: SOCE modulators for retinal and CNS disorders
• Technology: STIM1-targeting compounds with selectivity for pathological vs. physiological SOCE
• Relevance: Addresses neuronal calcium overload in AD while preserving synaptic function

Mitochondrial Calcium Modulators

Khlorum

• Headquarters: Boston, Massachusetts, USA
• Focus: Mitochondrial calcium uniporter (MCU) modulators
• Technology: Novel MCU blockers with selectivity for the mitochondrial pore vs. plasma membrane calcium channels
• Stage: Discovery
• Rationale: Blocking pathological mitochondrial calcium uptake prevents permeability transition pore opening and subsequent cell death[@soc_mcdonnell2024]
• Relevance: Addresses bioenergetic failure and cell death downstream of calcium overload in AD neurons

Neuro mitochond Therapeutics

• Headquarters: Munich, Germany
• Focus: Mitochondrial calcium homeostasis for neurodegeneration
• Technology: Mitochondrial calcium-sensing molecules that regulate MCU activity based on cellular metabolic state
• Stage: Preclinical
• Relevance: Selectively blocks mitochondrial calcium uptake under pathological conditions (high cytosolic calcium, oxidative stress) while preserving normal mitochondrial calcium signaling

Calmodulin Pathway Modulators

Accerise

• Program: ACC-CAL series — calmodulin-dependent kinase (CaMK) inhibitors
• Indication: Alzheimer's disease, Parkinson's disease
• Stage: Discovery
• Technology: Structure-based design targeting CaMKII and CaMKIV, which are overactivated by amyloid-beta and promote tau phosphorylation[@calmodulin_ad]
• Relevance: CaMKII inhibition reduces tau hyperphosphorylation while preserving synaptic plasticity

BioKyra (Academic Spinout)

• Origin: Karolinska Institutet spinout
• Focus: Calmodulin-regulated phosphodiesterase 1 (PDE1) inhibitors
• Technology: PDE1 inhibitors restore cAMP signaling disrupted by excessive calmodulin activity
• Stage: Lead optimization
• Relevance: PDE1 is activated by calcium/calmodulin; inhibition may improve synaptic function and memory in AD

Calcium Buffering Protein Modulators

SynapseDx

• Focus: Parvalbumin replacement and enhancement strategies
• Technology: Peptide mimetics of parvalbumin calcium-binding domains
• Stage: Discovery
• Relevance: Restoring parvalbumin in fast-spiking interneurons may normalize inhibitory tone and reduce network hyperexcitability in AD

L-Type and N-Type Calcium Channel Modulators (Specialized AD Focus)

Vanderbilt University / NIH Blueprint Program

• Institution: Vanderbilt University Medical Center
• Focus: Development of selective N-type (Cav2.2) calcium channel blockers with enhanced brain penetration for AD
• Technology: Peptide toxins and small molecules targeting Cav2.2 over Cav1.x channels
• Stage: Preclinical
• Relevance: N-type channel blockade reduces excitatory neurotransmitter release and protects against excitotoxicity

Merck & Co.

• Program: Previous research on L-type calcium channel blockers (nimodipine, isradipine) for AD showed limited efficacy
• Current Focus: Repositioning to Cav1.3-selective modulators (to avoid cardiovascular effects of broad L-type blockade) and R-type (Cav2.3) calcium channels
• Technology: Subtype-selective compounds with improved selectivity profiles
• Stage: Discovery
• Note: Earlier clinical trials with non-selective L-type blockers were largely negative, but Cav1.3 selectivity may improve the risk/benefit ratio
• See: [Merck](/companies/merck)

Pipeline Summary

| Company | Mechanism | Target | AD Program | Stage |
|---------|-----------|--------|------------|-------|
| CalciMedica | SOCE inhibitor | STIM1/ORAI1 | CM-02 | Preclinical |
| CalciMedica | CaSR modulator | Calcium-sensing receptor | CM series | Discovery |
| NodThera | CaSR/NLRP3 | Allosteric modulator | NT series | Discovery |
| Accerise | CaMK inhibitor | CaMKII/IV | ACC-CAL | Discovery |
| BioKyra | PDE1 inhibitor | Calmodulin pathway | BK series | Lead opt. |
| Khlorum | MCU blocker | Mitochondrial Ca2+ uptake | KH series | Discovery |
| SynapseDx | PV mimetic | Parvalbumin replacement | SY series | Discovery |
| Kal Pharmaceuticals | CaSR PAM | Calcium-sensing receptor | KP-001, KP-002 | Preclinical |
| Vanderbilt/NIH | N-type blocker | Cav2.2 | Research program | Preclinical |

Therapeutic Rationale and Clinical Strategy

Why Calcium Homeostasis?

Calcium dysregulation is one of the earliest and most consistent features of AD, preceding amyloid and tau pathology[@laferla2002]. The calcium hypothesis posits that:

Advantages of Subcellular Targeting

Compared to traditional L-type/T-type channel blockers, subcellular calcium modulators offer:

• Selectivity: Target only pathological calcium signals, preserving normal synaptic function
• Disease-modifying potential: Address upstream calcium dysregulation rather than downstream symptoms
• Combination potential: Complement amyloid/tau-targeting therapies without mechanism conflict

Clinical Development Considerations

• Biomarkers: Calcium imaging (GCaMP fiber photometry), mitochondrial calcium sensors (mitPerCP), synaptic markers
• Genetic stratification: CACNA1C (L-type), CALM1/CALM2 (calmodulin), STIM1/ORAI1 variants may inform patient selection
• Imaging endpoints: PET calcium reporters under development for human use
• Combination: Pairing calcium homeostasis modulators with anti-amyloid or anti-tau therapies may enhance disease modification

Related Mechanisms

• [Calcium Dysregulation in Alzheimer's Disease](/mechanisms/calcium-dysregulation-ad)
• [Calcium Dysregulation Pathway](/mechanisms/calcium-dysregulation-pathway)
• [Calcium Dysregulation: Alzheimer's Disease](/mechanisms/calcium-dysregulation-alzheimers)
• [Calcium Dysregulation: Neurodegeneration](/mechanisms/calcium-dysregulation-neurodegeneration)
• [Calcium Dysregulation in Parkinson's Disease](/mechanisms/calcium-dysregulation-parkinsons)
• [Mitochondrial Calcium in Neurodegeneration](/mechanisms/mitochondrial-calcium-neurodegeneration)
• [Excitotoxicity in Alzheimer's Disease](/mechanisms/excitotoxicity)
• [Neuroinflammation: Calcium Signaling](/mechanisms/neuroinflammation-calcium-signaling)

Related Company Pages

• [Alzheimer's Disease Ion Channel Modulator Companies](/companies/ad-ion-channel-modulator-companies)
• [CalciMedica](/companies/calcimedica)
• [Accerise](/companies/accerrise)

External Links

• [PubMed - Calcium Homeostasis AD](https://pubmed.ncbi.nlm.nih.gov/?term=calcium+homeostasis+Alzheimer+therapeutics)
• [ClinicalTrials.gov - Calcium AD](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=calcium+channel)
• [Nature Reviews Neuroscience - Calcium PD](https://pubmed.ncbi.nlm.nih.gov/37855612/)

References